JPH11509844A5 - - Google Patents

Info

Publication number
JPH11509844A5
JPH11509844A5 JP1997506964A JP50696497A JPH11509844A5 JP H11509844 A5 JPH11509844 A5 JP H11509844A5 JP 1997506964 A JP1997506964 A JP 1997506964A JP 50696497 A JP50696497 A JP 50696497A JP H11509844 A5 JPH11509844 A5 JP H11509844A5
Authority
JP
Japan
Prior art keywords
nmda
sulfate
response
5β3βs
5β3αs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997506964A
Other languages
English (en)
Japanese (ja)
Other versions
JP4313435B2 (ja
JPH11509844A (ja
Filing date
Publication date
Priority claimed from US08/559,442 external-priority patent/US5888996A/en
Application filed filed Critical
Priority claimed from PCT/US1996/012198 external-priority patent/WO1997003677A1/en
Publication of JPH11509844A publication Critical patent/JPH11509844A/ja
Publication of JPH11509844A5 publication Critical patent/JPH11509844A5/ja
Application granted granted Critical
Publication of JP4313435B2 publication Critical patent/JP4313435B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50696497A 1995-07-24 1996-07-24 プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 Expired - Fee Related JP4313435B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US143995P 1995-07-24 1995-07-24
US60/001,439 1995-07-24
US50775795A 1995-07-26 1995-07-26
US08/507,757 1995-07-26
US08/559,442 1995-11-15
US08/559,442 US5888996A (en) 1995-07-26 1995-11-15 Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
PCT/US1996/012198 WO1997003677A1 (en) 1995-07-24 1996-07-24 Inhibition of nmda receptor activity by pregnenolone sulfate derivatives

Publications (3)

Publication Number Publication Date
JPH11509844A JPH11509844A (ja) 1999-08-31
JPH11509844A5 true JPH11509844A5 (https=) 2009-05-07
JP4313435B2 JP4313435B2 (ja) 2009-08-12

Family

ID=27356924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50696497A Expired - Fee Related JP4313435B2 (ja) 1995-07-24 1996-07-24 プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制

Country Status (4)

Country Link
US (1) US6083941A (https=)
EP (1) EP0840612A1 (https=)
JP (1) JP4313435B2 (https=)
WO (1) WO1997003677A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051599A1 (en) * 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
JP2002529416A (ja) 1998-11-10 2002-09-10 メディモド・リサーチ・インスティチュート・ゲーエムベーハー 嗜癖の治療のためのグルココルチコステロイド・レセプターおよび／またはミネラルコルチコステロイド・レセプターのアゴニスト、特にコルチコステロイドの使用
FR2786102B1 (fr) * 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US20040204490A1 (en) * 1999-08-31 2004-10-14 Farb David H. Effect of steroids on NMDA receptors depends on subunit composition
CA2383047A1 (en) 1999-08-31 2001-03-08 Trustees Of Boston University Effect of steroids on nmda receptors depends on subunit composition
GB0003524D0 (en) * 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
AU2002217841A1 (en) * 2000-11-06 2002-05-15 Trustees Of Boston University Neuroactive steroid derivatives and methods of use
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
US7790404B2 (en) * 2001-08-20 2010-09-07 Sanford-Burnham Medical Research Institute Excitatory glycine receptors and methods
AUPR731901A0 (en) * 2001-08-28 2001-09-20 Goodchild, Colin Stanley Method of treatment
FR2850023B1 (fr) * 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
IL154318A (en) 2003-02-06 2010-05-31 Sarah Herzog Memorial Hospital Pharmaceutical compositions for the treatment of movement disorders
EP1621199B8 (en) * 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
JP4664924B2 (ja) * 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
WO2005070950A1 (en) * 2004-01-15 2005-08-04 Warner Chilcott Company, Inc. Di-steroidal prodrugs of ethinyl estradiol
JP2007517877A (ja) * 2004-01-15 2007-07-05 ワーナー・チルコット・カンパニー・インコーポレーテッド エストラジオールのジ−ステロイド型プロドラッグ
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
CA2610481A1 (en) * 2005-07-12 2007-01-18 Warner Chilcott Company, Inc. 3-ester prodrugs of estradiol
CN101218245B (zh) * 2005-07-12 2011-08-17 沃纳奇尔科特有限责任公司 炔雌醇的3-酯前药
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
JP4382735B2 (ja) * 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
CA2623838A1 (en) * 2005-10-28 2007-05-03 Sun-Yeou Kim Extract of the family dioscoreaceae and composition for preventing or treating peripheral neuropathy comprising the same
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US20090203658A1 (en) * 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
WO2010077292A1 (en) * 2008-12-09 2010-07-08 King Faisal Specialist Hospital & Research Center Pregnenolone sulfate for the treatment of neurologic disorders
CA2848212C (en) * 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
FR2992645B1 (fr) * 2012-07-02 2014-08-01 Univ Claude Bernard Lyon Nouveaux derives de pyrrolidine
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CZ2014575A3 (cs) 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) * 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
EP3988096A1 (en) * 2020-10-26 2022-04-27 Universidad Pablo de Olavide OTRI Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
DE69435286D1 (de) * 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf

Similar Documents

Publication Publication Date Title
US6083941A (en) Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives
JPH11509844A5 (https=)
US5888996A (en) Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
KR101546031B1 (ko) Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 치료적 접근법
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
JP2021507944A (ja) 運動ニューロン疾患を含む神経障害のための組成物および治療方法
AU2006229840B2 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
EP3258930A1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
US8541395B2 (en) Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
Sadri‐Vakili et al. Inhibition of NMDA‐induced striatal dopamine release and behavioral activation by the neuroactive steroid 3α‐hydroxy‐5β‐pregnan‐20‐one hemisuccinate
US20110136769A1 (en) Method of treating men with testosterone supplement and 5alpha-reductase inhibitor
WO2024103012A1 (en) Polycyclic compounds for use in neurodegenerative conditions
EP1944041A1 (en) Therapeutic agent for neurogenic pain
JP2001513800A (ja) 医薬組成物調製のためのピバガビンの使用
CN116139140A (zh) 一种化合物在治疗糖皮质激素不良反应中的用途
Butler Effects of corticosterone and ethanol co-exposure on hippocampal toxicity: Potential role for the NMDA NR2B subunit